AIC
DNLI icon

Ameritas Investment Company’s Denali Therapeutics DNLI Stock Holding History

Ameritas Investment Company’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-200
Closed -$11.4K – 1053
2021
Q1 		$11.4K Buy
+200
New +$13.4K ﹤0.01% 1482

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameritas Investment Company's DNLI Position: Q2 2021 in Review

Ameritas Investment Company sold out of Denali Therapeutics (DNLI) in Q2 2021, closing a stake of 200 shares — an estimated $11.4K sold.

Ameritas Investment Company first reported a position in DNLI in Q1 2021 and held it in 1 quarter. The position peaked at $11.4K in Q1 2021. 210 funds tracked by Wall St. Rank hold DNLI as of Q2 2021.

  • Ameritas Investment Company reported no remaining Denali Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Company sold 200 Denali Therapeutics shares in Q2 2021, an estimated $11.4K.
  • Ameritas Investment Company first reported a position in Denali Therapeutics in Q1 2021 and held it in 1 quarter.
  • Ameritas Investment Company's Denali Therapeutics position peaked at $11.4K in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2021.

Based on Ameritas Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.